International Congress of Parkinson's Disease and Movement Disorders 2019
The 2019 International Parkinson and Movement Disorder Society (MDS), held September 22-26, 2019 in Nice, France, joins together thousands of clinicians, researchers, and industry supporters to present and discuss the latest data and hot topics related to the diagnosis, treatment, and management of movement disorders.
The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.
The clinical development of ND0612 includes 2 doses; a low dose for mid-stage Parkinson patients experiencing loss of motor control on oral therapy, and a high dose for severe disease in which oral drugs are no longer effective.
Data of amantadine (Gocovri, Adamas) extended-release tablets suggested that the therapy is, in fact, safe and tolerable with a unique pharmacokinetic profile, and results in significant improvements in dyskinesia for patients with Parkinson disease.